NewslettersPancreatic Cell NewsA First-in-Class Pan-Lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic CancerBy lbeveridge - August 30, 20230242Using small-molecule drug-design approaches, the authors generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor.[Nature Cancer]Full Article